Products with
Antioxidants bioactivity
Cat.No.
|
Product Name
|
BCN5974 |
Demethoxycurcumin
|
Demethoxycurcumin is a potential additive natural product in combination with chemotherapeutic agents in drug-resistant cancers, which has anti-acanthamoebic, anti-proliferative, antimetastatic, anti-inflammatory, antioxidant activities. It inhibited P-glycoprotein-mediated ATP hydrolysis under concentrations of <1 μM and efficiently inhibited 200 μM verapamil-stimulated ATPase activity. |
BCN5975 |
Bisdemethoxycurcumin
|
Bisdemethoxycurcumin is a natural derivative of curcumin with antiulcer, antioxidant, anti-inflammatory and anti-cancer activities, it suppresses MCF-7 cells proliferation by inducing ROS accumulation and modulating senescence-related pathways. Bisdemethoxycurcumin induces apoptosis in activated HSCs, but not in hepatocytes, by impairing cellular energetics and causing a downregulation of cytoprotective proteins, likely through a mechanism that involves CBR2. |
BCN5978 |
Stevenleaf
|
1. Gypenosides (Gyp, Stevenleaf) induce apoptosis in human hepatoma cells through the up-regulation of Bax and Bak, and down-regulation of Bcl-2, release of mitochondrial cytochrome c and activation of caspase cascade.
2. Gypenosides induce ER stress and production of reactive oxygen species and Ca 2+ , change the ratio of Bcl-2 and Bax, followed by the dysfunction of mitochondria, cause cytochrome c release, activation of caspase-3 before leading to apoptosis, these results provide information towards an understanding of the mechanisms by which Gyp induces cell cycle arrest and apoptosis in human tongue cancer cells.
3. Gypenosides can inhibit invasion and migration of human tongue SCC4 cells by down-regulating proteins associated with these processes, resulting in reduced metastasis.
4. Gypenosides imply their remarkable preventative and therapeutic potential in treatment of neurological diseases involving glutamate and oxidative stress.
5. The extensive antioxidant effect of gypenosides may be valuable to the prevention and treatment of various diseases such as atherosclerosis, liver disease and inflammation. |
BCN5979 |
Caffeic acid
|
Caffeic acid has antidiabetic, antioxidant, anticarcinogenic, and anti-inflammatory activities, it can suppress ultraviolet B(UVB)-induced COX-2 expression by blocking Fyn kinase activity, inhibits HBV-DNA replication as well as HBsAg production, also reduces serum DHBV level in DHBV-infected duckling model. Caffeic acid may be used as designed novel therapeutic drugs for Parkinson's disease by inhibiting α-synuclein fibrillation. |
BCN5980 |
Lipoic acid
|
Alpha-lipoic acid has become a common ingredient in multivitamin formulas, anti-aging supplements, and even pet food, it is well-defined as a therapy for preventing diabetic polyneuropathies, and scavenges free radicals, chelates metals, and restores intracellular glutathione levels which otherwise decline with age. Alpha-lipoic acid has therapeutic effects on joint inflammation and erosion in an animal model via NF-kappa B down regulation, it inhibits TNF-alpha induced NF-kappa B activation through blocking of MEKK1-MKK4-IKK signaling cascades. Lipoic acid is a novel treatment for Alzheimer's disease and related dementias. |